Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:darunavir
|
| gptkbp:approvalYear |
2006
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
J05AE10
|
| gptkbp:CASNumber |
206361-99-1
|
| gptkbp:chemicalFormula |
C27H37N3O7S
|
| gptkbp:combines |
gptkb:cobicistat
gptkb:ritonavir |
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:drugClass |
protease inhibitor
|
| gptkbp:form |
gptkb:tablet
oral suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
Prezista
|
| gptkbp:isPatentProtected |
no
|
| gptkbp:KEGGID |
D03659
|
| gptkbp:legalStatus |
Rx-only
|
| gptkbp:manufacturer |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:MedlinePlusID |
a607045
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:PubChem_CID |
213039
CHEMBL193 DB01264 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache rash |
| gptkbp:UNII |
YO603Y8113
|
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:Janssen_Pharmaceuticals
|
| gptkbp:bfsLayer |
5
|